Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by Pareto8020on Sep 16, 2022 2:20pm
144 Views
Post# 34967550

RE:RE:Feline patent action for BOEHRINGER INGELHEIM ANIMAL HEALTH

RE:RE:Feline patent action for BOEHRINGER INGELHEIM ANIMAL HEALTH You would think with the Allergan "MEGA" deal, pending clinical trial for their Botox killer (according to HV), pending deal for in the feline diabetes realm, new application of their SGLT2, management reorg, + SBM having to post their financials in a couple weeks which should disclose the upfront payment so big it made Howard smile that the shareprice would be ramping up in price and volume. 

Instead..... anemic volume and a few pennies away from 52 week low.  I put most if not all the reason behind this lack of enthusiasm regarding Sirona and thier prospects at the feet of their fearless CEO Howard V.  Years of over promising and not delivering + lack of general communication have eroded any faith in this play.  It has become the show-me stock cause unless they acutally show the details of the deal or a signed contract the market isn't pricing anything into this play.  They simply don't believe Howard can execute based on past performance - for good reason - cause he hasn't executed.  He has fumbled his way along for so many years the only reason they have signed any contracts is because of their technology in spite of the CEO's learn as you go methodology.  
<< Previous
Bullboard Posts
Next >>